Bacterial Meningitis Flashcards

1
Q

FYI : Meningococcal = Pneumococcal = Streptococcal =

A

Meningococcal = N. meningitidis Pneumococcal = S. pneumoniae Streptococcal† = Group A/B Streptococcus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Listeria risk factor

A

Alcoholism Immunocompromised state Age < 1 month Age > 50 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

FYI: Risk factors for bacterial menigitis (BM)

A

Head trauma Otitis media Sinusitis or mastoiditis Neurosurgery Dermal sinus tracts Systemic sepsis Immunosuppression High-dose (long-term) steroids Immunoglobulin deficiency Chemotherapy Splenectomy Sickle Cell disease Exposure to cigarette smoke - Meningococcal Cochlear implants - Pneumococcal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Systematic complication for BM

A

Sepsis (FYI) Disseminated intravascular coagulation Acute respiratory distress syndrome Septic/reactive arthritis Typically a result of bacteremia that often accompanies meningitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Neurologic complication for BM

A

Altered mental status Confusion, lethargy, coma Increased intracranial pressure and cerebral edema Mild to Moderate: HA, confusion, irritability, N/V Severe: Coma, vision loss, cerebellar herniation Seizures Focal neurologic deficits Cranial nerve palsy, hemiparesis, aphasia, ataxia Cerebrovascular abnormalities Thrombosis, vasculitis, aneurysm, hemorrhage Sensorineural hearing loss Intellectual impairment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Likely etiology by age groups

A

Newborn - 1 months and > 50 years old: Group B Streptococcus, E. coli, Klebsiella, Enterobacter, Listeria monocytogenes 1 month - 50 years old: S. pneumoniae, N. meningitidis, H. influenzae

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Clinical Presentation of BM

A

Varies with age Classic Tetrad (≥ 2 of 4 sxs in > 90% of adults w/ ABM) -Fever -Nuchal rigidity -Altered mental status -Headache Signs Kernig sign Brudzinski sign Dermatological Manifestations Purpuric and petechial skin lesions Other symptoms Chills, vomiting, and photophobia Bulging fontanelle, irritability, refusal to eat, apnea, purpuric rash, and convulsions in young children

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

FYI: Nuchal rigidity

A

Impaired neck flexion resulting from muscle spasm (not actual rigidity) of the extensor muscles of the neck; usually attributed to meningeal irritation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Kernig sign

A

The thigh is flexed at the hip and knee at 90 degree angles, and subsequent extension in the knee is painful (leading to resistance). This may indicate subarachnoid hemorrhage or meningitis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Brudzinski sign

A

Severe neck stiffness causes a patient’s hips and knees to flex when the neck is flexed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Goal of therapy

A

Relieve signs/symptoms of infection Eradicate infection Avoid/resolve additional infectious problems E.g., CNS deterioration Prevent complications associated with antimicrobial therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Lumbar Puncture and complications

A

Puncture into subarachnoid space of lumbar region to obtain spinal fluid for diagnostic or therapeutic purposes (aka LP or spinal tap) Complications: - Headache - Back discomfort or pain - Bleeding - Brainstem herniation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Lumbar Puncture: CSF Evaluation

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

FYI: Delayed Lumbar Puncture

A

•LP after CT scan to identify possible CNS mass lesion

oAltered mentation

oFocal neurologic signs

oPapilledema

oSeizure within the previous week

oImpaired cellular immunity

•Possible Contraindications to LP (populations above)*

oPossible raised intracranial pressure

oThrombocytopenia or other bleeding predisposition (including ongoing anticoagulant therapy)

oSuspected spinal epidural abscess

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the suspected organism for GPCs in pairs and chains?

A

Streptococcus pneumoniae

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the suspected organism for Gram (-) diplococcus?

A

Neisseria meningitidis

17
Q

What is the suspected organism for Gram (+) bacilli (rods)?

A

Listeria monocytogenes

18
Q

What is the suspected organism for Gram (-) coccobacillus?

A

Haemophilus influenzae

19
Q

What is the recommended and alternative (FYI) for Streptococcus Pneumoniae?

A

Recommended: Vanco + 3rd gen Ceph

Alternative: Moxifoxacin

20
Q

What is the recommended and alternative (FYI) for Neissria Meningitidis?

A

Recommended: 3rd gen Cephalosporin

Alternative: Fluoroquinolone and Aztreonam

21
Q

What is the recommended and alternative (FYI) for Listeria Monocytogenes?

A

Recommended: Amp +/- AG OR PCN +/- AG

Alternative: Bactrim

22
Q

What is the recommended and alternative (FYI) for Haemophilus influenza?

A

Recommended: 3rd gen ceph

Alternative: Cefepime, Meropenem, Fluoroquinolone

23
Q

Duration of therapy

A
24
Q

ABx dosing for BM

A
25
Q

Dexamethasone MOA and pt population benefit

A

•Inhibit production of proinflammatory cytokines

oTNF and IL-1

•Benefit in infants and children with H. influenzae and in adults with S. pneumoniae meningitis

26
Q

Dexamethasone advantage and disadvantage

A

•Advantage: may decrease neurologic sequelae, unfavorable outcome, and death

oE.g., cerebral edema, ↑ ICP, altered cerebral blood flow, neuronal injury

•Disadvantage: might reduce CSF concentrations of antibiotics due to decreased inflammation

27
Q

Adjunctive Dexomethasone for infants and children ( >6 wks old)

A

oDexamethasone 0.15 mg/kg IV q6h x 2- 4 days

oMust be given 10-20 minutes prior to or with first dose of antibiotics for benefit

28
Q

Adjunctive Dexamethasone for adults suspected/proven pneumococcal infxn:

A

oDexamethasone 10 mg IV q6h x 2- 4 days

oMust be given 10-20 minutes prior to or with first dose of antibiotics for benefit

29
Q

•Daily Monitoring (short-term therapy) for Dexamethsone

A

oHemoglobin

oOccult blood loss

oSerum potassium

oBlood glucose

30
Q

Monitoring for BM

A

•Symptom-based

oResolution of s/sxs over time (neurologic fxn, fever, pain, etc.)

•Microbiologic eradication

oCheck blood cultures q24h until negative

oRepeat LP not routinely recommended, but consider if no improvement within 48h on appropriate therapy

•Laboratory

oCBC, SCr

oSerum drug concentration monitoring (vancomycin, AGs)

•Safety

oADRs to pharmacologic therapy

31
Q

FYI: Antibiotics may be prescribed for close contacts of patients with meningococcal meningitis

A

oProphylaxis: Ciprofloxacin 500 mg po x 1

oAlternate: Ceftriaxone 250 mg IM x 1

32
Q

FYI: Prophylaxis for H. Influenzae Meningitis

A

•Antibiotics may be prescribed for close contacts in the entire household of a patient with severe H. influenzae meningitis – IF there is a high-risk person within the household

oProphylaxis: rifampin 600 mg/d x 4 days

oAlternate: ciprofloxacin 500 mg x 1

•Prophylaxis not recommended for adults who are vaccinated

33
Q

FYI: List 2 MenB vaccine

A

•Limited Guidance

Trumenba® (Approved 10/14): 3 doses

Bexsero® (Approved 1/15): 2 doses

34
Q

FYI: List 3 Meningococcal vaccines quadrivalent (Serogroups A, C, W-135, and Y)

A

two conjugate vaccines (MCV-4), Menactra and Menveo, and

one polysaccharide vaccine (MPSV-4), Menomune, produced by Sanofi Pasteur.

35
Q

FYI: Limitation of MPSV-4 vaccine

A

The duration of immunity mediated by Menomune (MPSV-4) is three years or less in children aged under 5 because it does not generate memory T cells. Attempting to overcome this problem by repeated immunization results in a diminished, not increased, antibodyresponse, so boosters are not recommended with this vaccine.

As with all polysaccharide vaccines, Menomune does not produce mucosal immunity, so people can still become colonised with virulent strains of meningococcus, and no herd immunity can develop.For this reason, Menomune is suitable for travelers requiring short-term protection, but not for national public health prevention programs.

Menveo and Menactra contain the same antigens as Menomune, but the antigens are conjugated to a diphtheria toxoid polysaccharide–protein complex, resulting in anticipated enhanced duration of protection, increased immunity with booster vaccinations, and effective herd immunity.

36
Q

FYI: N. meningitidis Vaccines pt age and population

A

•VACCINATION OPTIONAL: Patients 16-23 y/o

oPreferably 16-18 y/o

•VACCINATION RECOMMENDED:

oPersons w/ persistent complement component deficiencies

oPersons with anatomic or functional asplenia

oMicrobiologists routinely exposed to isolates of N. meningitidis

oPersons identified as at increased risk because of a serogroup B meningococcal disease outbreak